Advanced search
1 file | 4.85 MB

Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells

(2017) ONCOTARGET. 8(40). p.68208-68220
Author
Organization
Abstract
Induction of necroptosis has emerged as an alternative approach to trigger programmed cell death, in particular in apoptosis-resistant cancer cells. Recent evidence suggests that kinase inhibitors targeting oncogenic B-RAF can also affect Receptor-interacting serine/threonine-protein kinase (RIP) 1 and RIP3. Sorafenib, a multi-targeting kinase inhibitor with activity against B-RAF, is used for the treatment of acute leukemia. In the present study, we therefore investigated whether Sorafenib interferes with therapeutic induction of necroptosis in acute leukemia. Here, we report that Sorafenib inhibits necroptotic signaling and cell death in two models of necroptosis in acute leukemia. Sorafenib significantly reduces Second mitochondria-derived activator of caspases (Smac) mimetic-induced necroptosis in apoptosis-resistant acute myeloid leukemia (AML) cells as well as Smac mimetic/Tumor Necrosis Factor (TNF)alpha-induced necroptosis in FADD-deficient acute lymphoblastic leukemia (ALL) cells. Sub- to low micromolar concentrations of Sorafenib corresponding to its plasma levels reported in cancer patients are sufficient to inhibit necroptosis, emphasizing the clinical relevance of our findings. Furthermore, Sorafenib blocks Smac mimetic-mediated phosphorylation of mixed-lineage kinase domain-like protein (MLKL) that marks its activation, indicating that Sorafenib targets components upstream of MLKL such as RIP1 and RIP3. Intriguingly, Sorafenib reduces the Smac mimetic/TNF alpha-stimulated interaction of RIP1 with RIP3 and MLKL, demonstrating that it interferes with the assembly of the necrosome complex. Importantly, Sorafenib significantly protects primary, patient-derived AML blasts from Smac mimetic-induced necroptosis. By demonstrating that Sorafenib limits the anti-leukemic activity of necroptosisinducing drugs in acute leukemia cells, our study has important implications for the use of Sorafenib in the treatment of acute leukemia.
Keywords
MIXED LINEAGE KINASE, BYPASSES APOPTOSIS RESISTANCE, ALPHA-DEPENDENT, APOPTOSIS, MYELOID-LEUKEMIA, DOMAIN-LIKE, TNF-ALPHA, DEATH, NECROSIS, RIP3, CANCER, necroptosis, cell death, Sorafenib, Smac, leukemia

Downloads

  • 2914 17Feldmann.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 4.85 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Feldmann, Friederike, Barbara Schenk, Sofie Martens, Peter Vandenabeele, and Simone Fulda. 2017. “Sorafenib Inhibits Therapeutic Induction of Necroptosis in Acute Leukemia Cells.” Oncotarget 8 (40): 68208–68220.
APA
Feldmann, F., Schenk, B., Martens, S., Vandenabeele, P., & Fulda, S. (2017). Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells. ONCOTARGET, 8(40), 68208–68220.
Vancouver
1.
Feldmann F, Schenk B, Martens S, Vandenabeele P, Fulda S. Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells. ONCOTARGET. 2017;8(40):68208–20.
MLA
Feldmann, Friederike, Barbara Schenk, Sofie Martens, et al. “Sorafenib Inhibits Therapeutic Induction of Necroptosis in Acute Leukemia Cells.” ONCOTARGET 8.40 (2017): 68208–68220. Print.
@article{8534173,
  abstract     = {Induction of necroptosis has emerged as an alternative approach to trigger programmed cell death, in particular in apoptosis-resistant cancer cells. Recent evidence suggests that kinase inhibitors targeting oncogenic B-RAF can also affect Receptor-interacting serine/threonine-protein kinase (RIP) 1 and RIP3. Sorafenib, a multi-targeting kinase inhibitor with activity against B-RAF, is used for the treatment of acute leukemia. In the present study, we therefore investigated whether Sorafenib interferes with therapeutic induction of necroptosis in acute leukemia. Here, we report that Sorafenib inhibits necroptotic signaling and cell death in two models of necroptosis in acute leukemia. Sorafenib significantly reduces Second mitochondria-derived activator of caspases (Smac) mimetic-induced necroptosis in apoptosis-resistant acute myeloid leukemia (AML) cells as well as Smac mimetic/Tumor Necrosis Factor (TNF)alpha-induced necroptosis in FADD-deficient acute lymphoblastic leukemia (ALL) cells. Sub- to low micromolar concentrations of Sorafenib corresponding to its plasma levels reported in cancer patients are sufficient to inhibit necroptosis, emphasizing the clinical relevance of our findings. Furthermore, Sorafenib blocks Smac mimetic-mediated phosphorylation of mixed-lineage kinase domain-like protein (MLKL) that marks its activation, indicating that Sorafenib targets components upstream of MLKL such as RIP1 and RIP3. Intriguingly, Sorafenib reduces the Smac mimetic/TNF alpha-stimulated interaction of RIP1 with RIP3 and MLKL, demonstrating that it interferes with the assembly of the necrosome complex. Importantly, Sorafenib significantly protects primary, patient-derived AML blasts from Smac mimetic-induced necroptosis. By demonstrating that Sorafenib limits the anti-leukemic activity of necroptosisinducing drugs in acute leukemia cells, our study has important implications for the use of Sorafenib in the treatment of acute leukemia.},
  author       = {Feldmann, Friederike and Schenk, Barbara and Martens, Sofie and Vandenabeele, Peter and Fulda, Simone},
  issn         = {1949-2553},
  journal      = {ONCOTARGET},
  keyword      = {MIXED LINEAGE KINASE,BYPASSES APOPTOSIS RESISTANCE,ALPHA-DEPENDENT,APOPTOSIS,MYELOID-LEUKEMIA,DOMAIN-LIKE,TNF-ALPHA,DEATH,NECROSIS,RIP3,CANCER,necroptosis,cell death,Sorafenib,Smac,leukemia},
  language     = {eng},
  number       = {40},
  pages        = {68208--68220},
  title        = {Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells},
  url          = {http://dx.doi.org/10.18632/oncotarget.19919},
  volume       = {8},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: